Peptides and Ehlers-Danlos syndrome: what to know before trying one

Reviewed 31 sourcesPublished by PepVault

No study has tested BPC-157, TB-500, GHK-Cu or collagen peptides in EDS. Who the healing studies included, why vascular EDS matters most, and who decides.

Woman in a lavender sports top pulls a green resistance band looped round a porch post
Last reviewed
Sources
31
Questions
9
Compounds
6

The short answer

No study has tested BPC-157, TB-500, GHK-Cu or collagen peptides in people with Ehlers-Danlos syndrome: a November 2026 search of PubMed and ClinicalTrials.gov found none. Their healing data come from rats and from people without EDS, whose collagen genes work normally. The type matters most: in vascular EDS, arteries can tear, so any new compound is a decision for the vascular EDS team.

Every number checked at its primary source · · 31 sources · How we research

Evidence: No study has tested BPC-157, TB-500, GHK-Cu, collagen peptides or a GLP-1 drug in EDS; their data come from animals and from people without EDS, and the randomized drug trials in EDS are in the vascular type.

Woman in a lavender sports top pulls a green resistance band looped round a porch post

Has any peptide been studied in Ehlers-Danlos syndrome?

Not the ones people ask about. On November 20, 2026 we searched PubMed for each compound together with Ehlers-Danlos or hypermobility, and ClinicalTrials.gov for trials that pair them12. PubMed holds 9,682 records on Ehlers-Danlos syndrome (EDS) or hypermobility, and ClinicalTrials.gov lists 101 studies of EDS. The compounds below appear in none of them.

CompoundPubMed records with EDS or hypermobilityTrials registered in EDS or hypermobility
BPC-1570 (one hit, a 1987 paper on another syndrome)0
TB-500 or thymosin beta-400
GHK-Cu (copper peptide)00
Collagen peptides as a supplement0 (a few lab papers on collagen in EDS; none tested a supplement)0
Semaglutide, tirzepatide or liraglutide00

Two peptides have been given to people with EDS, and neither is one of these. In Copenhagen, 5 people with classical EDS and 10 matched controls had IGF-I, a growth factor, injected into one kneecap tendon and saline into the other. The EDS tendons built protein at a normal rate to begin with, and IGF-I raised that rate in the EDS group but not in the controls3. A trial of oxytocin, a small peptide hormone, for pain in hypermobile EDS closed after enrolling 2 people, with 1 completing both arms4.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault records the site with each injected dose and keeps a side-effect log with a severity and a date, so a bruise that keeps coming back at one spot shows up in your own record.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What is Ehlers-Danlos syndrome, and why does the type matter?

EDS is a group of inherited conditions of connective tissue, the tissue that holds skin, joints and blood vessels together. The 2017 international classification names 13 types, marked by loose joints, stretchy skin and fragile tissue. Most are caused by a change in a collagen gene or in a gene for an enzyme that finishes collagen, and all but one are confirmed by a genetic test5.

The exception is the hypermobile type (hEDS), diagnosed from its signs because, in most people with it, no cause has been found56. Hypermobile and classical EDS are the most common, and together all the types affect at least 1 in 5,000 people6. Classical EDS comes mostly from the COL5A1 or COL5A2 genes, with wounds that split open easily and skin that bruises easily6. Vascular EDS (vEDS) comes from COL3A1, the gene for type III collagen, a main protein of artery walls and hollow organs, and affects about 1 in 50,000 to 1 in 200,000 people7.

  • Hypermobile EDS: no known gene in most people; joint pain, instability and the overlap conditions further down.
  • Classical EDS: type V collagen; fragile, stretchy skin, wounds that split, easy bruising.
  • Vascular EDS: type III collagen; arteries, bowel and uterus can tear.

Why does vascular EDS change everything?

Because the risk is in the arteries, not the joints. In 220 people with vEDS and 199 affected relatives, more than 80% of the 220 had a major complication by age 40, most deaths came from a torn artery, and median survival was 48 years8. That is why the trials in vEDS test blood-pressure drugs, not healing compounds.

TrialWhoWhat was givenArterial events
BBEST, France and Belgium, 2010953 people with vEDS, followed about 4 yearsCeliprolol, a beta blocker, or no treatment20% on celiprolol against 50% without; stopped early for benefit
ARCADE, France, 20251057 people with vEDS already on celiprolol, for 2 yearsIrbesartan, a blood-pressure drug, or placebo27.6% on irbesartan against 53.6% on placebo (arterial events or new lesions on scans)
DiSCOVER, US11150 plannedCeliprolol or placeboRecruiting; estimated to finish in 2029

The international care guidance for vEDS asks for a genetic diagnosis, a specialist team, blood pressure kept in the normal range, yearly scans of the arteries and a daily life arranged to avoid injury7. No peptide has been tested in vEDS. In chick embryos, rat muscle and human cells, BPC-157 grows new blood vessels31, and no one has studied what it does to arteries built from altered type III collagen. With vEDS, a new compound is a question for that team before anything else.

When to get help With vascular EDS, an artery or the bowel can tear without warning68: keep the emergency care plan your team gives you (the vascular EDS passport) with you, and show it to any emergency team7.

Who were BPC-157, TB-500, GHK-Cu and collagen tested in?

In rats, and in people whose collagen is normal. None of these studies was designed for EDS, and none reports enrolling anyone with it.

CompoundAnimal workPeople studiedPeople with EDS
BPC-157Rats; in a 2026 study of 32 rats with repaired Achilles tendons, it raised tendon strength, but not significantly1530 in three pilots: 16 with knee pain, 12 women with bladder pain, 2 healthy adults given it by IV121314None
TB-500 or thymosin beta-4In the same rat study, TB-500 made repaired tendons significantly stronger1540 healthy volunteers in a placebo-controlled IV safety study; 73 people with leg ulcers treated on the skin1617None
GHK-CuCell and animal wound studies (pepvault.app/guides/ghk-cu-skin-and-hair)13 people after laser skin resurfacing, with no difference on blinded measures; 86 with leg ulcers, where a GHK-Cu cream did no better than placebo1819None
Collagen peptidesRodent and cell work on bone21139 athletes with knee pain; 131 women past menopause; 20 people with Achilles tendon pain; 2,534 healthy adults in 35 skin trials20212223None

The collagen trials are the strongest set here: placebo-controlled, with modest gains on knee pain in sport, bone density and Achilles rehab202122. The full read is in pepvault.app/guides/bpc-157-human-data, pepvault.app/guides/bpc-157-and-tb-500 and pepvault.app/guides/collagen-vs-research-peptides, and each compound's library page (pepvault.app/peptides/bpc-157, pepvault.app/peptides/tb-500, pepvault.app/peptides/ghk-cu, pepvault.app/peptides/collagen-peptides) has its side effects.

Can a healing peptide fix a collagen gene?

No compound changes the gene, and that is the heart of the gap. In the rat studies, the tendon cells carried normal collagen genes, so a repair signal sped up a process that builds normal tissue15. In classical or vascular EDS, the altered gene is still there, and no study shows whether a repair signal builds normal tissue on top of it. Collagen peptides supply raw amino acids (pepvault.app/glossary/amino-acid); they do not change the gene's instructions either.

The Copenhagen IGF-I study is the one test of the idea in EDS. Its classical EDS patients made tendon protein at a normal rate, and their tendons answered a growth signal more strongly than the controls' did3. It measured six hours of protein building in 5 people. It did not measure whether the new tissue was normal or the tendon stronger. In hEDS, where no gene is known for most people, there is no study of what a repair signal acts on.

What should someone with EDS watch for with injections?

Bruising and numbing. Easy bruising runs through the EDS types, and fragile skin is common6. A small needle under the skin (pepvault.app/glossary/subcutaneous) can leave a bigger bruise in EDS than in most people, which is one more reason to move each shot to a new spot (pepvault.app/guides/injection-site-rotation).

Many people with EDS also report that local anaesthetics work poorly. A 2005 report described local anaesthetic failure in joint hypermobility, and Vanderbilt is now measuring it against healthy volunteers in a planned 230 people, because the reports have never had objective data2425.

PepVault records the site with each injected dose and keeps a side-effect log with a severity and a date, so a bruise that keeps coming back at one spot shows up in your own record. Log it in PepVault

Do mast cell problems, POTS and gut symptoms change the picture?

They change what to ask. A 2026 meta-analysis of 19 studies and 17,455 people with hEDS or hypermobility found that 65.3% had at least one chronic gut symptom, 41.3% had reflux disease, 35.9% had orthostatic intolerance (feeling faint or unwell when standing) and 21.9% had POTS, a heart rate that races on standing26. Mast cells, immune cells that release histamine, have been proposed as part of the picture27, but a 2026 Mayo Clinic report found no evidence that mast cell activation syndrome is more common in POTS or hEDS28.

This matters most for GLP-1 drugs (pepvault.app/glossary/glp-1), the most prescribed peptides. Wegovy and Zepbound both slow how fast the stomach empties, and both labels say they are not recommended in severe gastroparesis, a stomach that empties far too slowly2930. Wegovy raises resting heart rate by 1 to 4 beats a minute on average and Zepbound by 1 to 32930; in Wegovy's weight trials, 26% on the drug had a rise of 20 or more at some visit, against 16% on placebo29. No study has tested a GLP-1 drug in EDS1. With POTS or slow stomach emptying, those two label lines are the ones to raise with the prescriber (pepvault.app/peptides/semaglutide, pepvault.app/peptides/tirzepatide).

What do people with EDS report?

Commonly reported: people with hEDS most often bring up BPC-157 and TB-500 for joint and tendon pain, and GHK-Cu or collagen for skin; bruising at injection sites and numbing that wears off fast are frequent complaints, and many say their symptoms swing so much from week to week that a few weeks on anything is hard to read.

That last point is why notes from before and after help: pain and fatigue in hEDS rise and fall on their own.

Who decides, and what do you bring to that conversation?

The clinician who manages your EDS decides, and for vascular EDS, the vascular team. What these studies give that conversation is what was tested, and in whom.

  1. Know your type. Bring the genetic result if you have one; a vascular or classical result changes the conversation more than any study here57.
  2. Name the compound and how it would be taken: by mouth, on the skin or by injection under the skin.
  3. Say plainly what the evidence is: animal studies and small human pilots in people without EDS, and no study in EDS12.
  4. Raise bruising, slow-healing skin and numbing that fails, if you have them, before any injection.
  5. If a GLP-1 drug is on the table, raise POTS, a fast heart rate or slow stomach emptying, because both labels speak to them2930.
  6. Agree on what you will track and when you will look at it together.

PepVault's doctor's report gathers your doses, injection sites and side effects for a chosen protocol on one page, ready to show the clinician who manages your EDS. Log it in PepVault

Track it in the app

Sources

  1. PubMed searches run November 20, 2026: each compound AND (ehlers-danlos[tiab] OR "Ehlers-Danlos Syndrome"[MeSH] OR hypermobil*[tiab]); 9,682 records for that EDS term alone. pubmed.ncbi.nlm.nih.gov
  2. ClinicalTrials.gov searches run November 20, 2026: condition Ehlers-Danlos (101 studies) or hypermobility (116 studies), with each compound as the intervention (0 for each). clinicaltrials.gov
  3. Nielsen RH et al. Tendon protein synthesis rate in classic Ehlers-Danlos patients can be stimulated with insulin-like growth factor-I. J Appl Physiol. 2014. PubMed 25103963
  4. ClinicalTrials.gov NCT05405257. Oxytocin treatment for chronic pain in hypermobile Ehlers-Danlos syndrome. Baylor College of Medicine. Terminated. clinicaltrials.gov
  5. Malfait F et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017. PubMed 28306229
  6. MedlinePlus Genetics. Ehlers-Danlos syndrome. U.S. National Library of Medicine. Last updated July 29, 2022. medlineplus.gov
  7. Byers PH et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017. PubMed 28306228
  8. Pepin M et al. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000. PubMed 10706896
  9. Ong KT et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010. PubMed 20825986
  10. Jeunemaitre X et al. Efficacy of irbesartan in celiprolol-treated patients with vascular Ehlers-Danlos syndrome. Circulation. 2025. PubMed 39906986
  11. ClinicalTrials.gov NCT05432466. Celiprolol compared with placebo in vascular Ehlers-Danlos syndrome (DiSCOVER). Acer Therapeutics. Recruiting. clinicaltrials.gov
  12. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
  13. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PubMed 39325560
  14. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PubMed 40131143
  15. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PubMed 42542926
  16. Ruff D et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PubMed 20536472
  17. Guarnera G et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. PubMed 20536470
  18. Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PubMed 16847171
  19. Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PubMed 1495150
  20. Zdzieblik D et al. Improvement of activity-related knee joint discomfort following supplementation of specific collagen peptides. Appl Physiol Nutr Metab. 2017. PubMed 28177710
  21. König D et al. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women: a randomized controlled study. Nutrients. 2018. PubMed 29337906
  22. Praet SFE et al. Oral supplementation of specific collagen peptides combined with calf-strengthening exercises enhances function and reduces pain in Achilles tendinopathy patients. Nutrients. 2019. PubMed 30609761
  23. Batool A et al. Oral collagen peptides and skin rejuvenation: a systematic review and an updated meta-analysis of randomized controlled trials. J Cosmet Dermatol. 2026. PubMed 43047141
  24. Hakim AJ et al. Local anaesthetic failure in joint hypermobility syndrome. J R Soc Med. 2005. PubMed 15684369
  25. ClinicalTrials.gov NCT04036305. Local anesthetic response in Ehlers-Danlos syndrome (EDS) and healthy volunteers. Vanderbilt University Medical Center. clinicaltrials.gov
  26. Kulin D et al. Meta-analysis: chronic gastrointestinal symptoms and comorbidities in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Aliment Pharmacol Ther. 2026. PubMed 42437376
  27. Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017. PubMed 28261938
  28. Valdez JA et al. Lack of evidence for increased mast cell activation syndrome prevalence in postural orthostatic tachycardia syndrome and/or hypermobile Ehlers-Danlos syndrome. J Allergy Clin Immunol Pract. 2026. PubMed 42595300
  29. Wegovy (semaglutide) prescribing information, sections 5.6, 5.9 and 7.2. Novo Nordisk. DailyMed, version 19, June 30, 2026. dailymed.nlm.nih.gov
  30. Zepbound (tirzepatide) prescribing information, sections 5.2, 6.1 and 7.2. Eli Lilly. DailyMed, version 40, September 2, 2026. dailymed.nlm.nih.gov
  31. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PubMed 27847966

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo